Restoring immune balance. Transforming lives.

We innovate around the complexities of the immune system to treat the cause of autoimmune disease and not merely the symptoms.

;

About

Everything we do revolves around the immune system.

LAPIX is a clinical-stage biopharmaceutical company dedicated to pioneering an innovative and first-in-class treatment for people diagnosed with autoimmune disease. We have taken a patient-centric approach by developing a novel, orally administered, t-cell engager therapy that is not immunosuppresive. We believe there is a better, gentler way for treating patients with autoimmune diseases.

Our pursuit of restoring the body’s natural immune tolerance pathway reflects our passion to transform lives through the development of progressive and patient-centric therapies for people suffering from autoimmune diseases with dysregulated Tregs such as Atopic Dermatitis, Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, Multiple Sclerosis and many others.

Our antigen-agnostic t-cell engager approach is centered on developing a TIM (T-cell immunoglobulin and mucin domain) agonist and is combined with our in-depth knowledge of immunology and immune tolerance.

LPX-TI641 (our lead therapeutic) has been meticulously developed to offer safe, efficacious, and patient-focused solutions for addressing a broad spectrum of autoimmune conditions. Our vision is to transform how the medical field currently treats patients with immune-related diseases, and we are deeply committed to helping as many patients as possible.

Inspired to make a difference for patients.

Our vision of changing the way autoimmune diseases are treated necessitates groundbreaking ways of thinking. Our antigen-agnostic, orally administered t-cell engager approach unleashes the power of immune tolerance by addressing the root cause of autoimmune disease. In doing so, we are enabling a treatment paradigm that breaks free from the shackles of yesteryear immune tolerance technology that has held back the field.”

Anas Fathallah, Ph.D.

Chief Executive Officer and Co-Founder

We are at the precipice of unlocking the full potential of TIM receptors and transforming the approach that scientific and medical communities utilize to treat auto-immune diseases.”

Nimita Dave, Ph.D.

Clinical Pharmacology, Drug Metabolism and Pharmacokinetics

Approach

We are unlocking the TIM pathway to explore new treatment options for autoimmune diseases.

By challenging the conventional treatment approach of immune system suppression, and shifting it to our novel, t-cell engager approach, we are discovering new possibilities for patients diagnosed with autoimmune diseases

Our methodology for treating autoimmune disease through the TIM pathway relies on engaging the TIM receptors (TIM-3, TIM-4) with high-potency induction in an antigen-agnostic manner. This first-of-its-kind solution will replace existing treatments for autoimmune disease. Instead of suppressing the immune system, our therapies reestablish immune balance by restoring Treg and Breg populations to regulate pathogenic T cells.

TIM is exclusively expressed on immune cells and represents the body’s inherent tolerance pathway. Our unique and potent molecules activation of TIM restores immune equilibrium and reduces the harmful effects of renegade immune cells. Our therapies restore Tregs and Bregs (which are typically downregulated in autoimmune disease), while also downregulating pathogenic TH17, TH1 and TH2 (which are typically upregulated by autoimmune disease).

We believe correcting the ratio of Tregs to TH17 and TH1 (in diseases like RA) and Tregs to TH2 (in TH2 mediated diseases like AD and even non autoimmune diseases like asthma) is crucial to the treatment of these patients.

TIM Pathway

The Tim (T-cell immunoglobulin and mucin domain) pathway is the linchpin in immune regulation.

The TIM pathway is a complex network of interactions involving the TIM family of proteins. We believe that it is the starting point for identifying the root cause — and potential cure — of immune-related diseases. These proteins are vital to regulating T cell responses, inflammation and various immune-related disorders.

The TIM pathway was discovered in the early 2000s and validated by vast research over the last 20 years. We concentrate on the Tim family of receptors, specifically TIM-3 and TIM-4, because of their central and influential role in immune regulation. The body’s ability to effectively engage TIM is lost during chronic inflammation and can lead to loss of tolerance to self. The end result can be the development or exacerbation of autoimmune diseases, causing the immune system to mistakenly attack and damage itself.

Our therapeutics are orders of magnitude more potent than TIM’s endogenous ligands and can effectively engage and activate TIM, even under inflammatory conditions. Our data shows that by activating TIM-3 and TIM-4 receptors to restore immune balance, we can treat autoimmune diseases without impacting the immune system’s other functionality, and without inducing neutropenia and lymphocytopenia. The induction of neutropenia and lymphocytopenia in patients is a major drawback to existing autoimmune therapies.

Pipeline

We are advancing LPX-TI641 through the clinic.

Program

Indication

Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3

LPX-TI641

A clinical stage, first-in-class treatment for autoimmune diseases, LPXTI-641 upregulates Tregs and Bregs while downregulating Th17, TH1 and TH2 in an antigen agnostic manner.

Rheumatology

Rheumatoid Arthritis (RA)

Dermatology

Atopic Dermatitis
Psoriasis

LPX-TI641

A clinical stage, first-in-class treatment for autoimmune diseases, LPXTI-641 upregulates Tregs and Bregs while downregulating Th17, TH1 and TH2 in an antigen agnostic manner.

Indication

Rheumatology